Effect of antibody to capsular polysaccharide on eosinophilic pneumonia in murine infection with Cryptococcus neoformans

Journal of Infectious Diseases

Volumn 177, Issue 6, 1998, Pages 1639-1646

  Feldmesser, Marta ^a   Kress, Yvonne ^a   Casadevall, Arturo ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2B; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN M ANTIBODY; MANNAN; MONOCLONAL ANTIBODY; POLYSACCHARIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLONY FORMING UNIT; CONTROLLED STUDY; CRYPTOCOCCUS NEOFORMANS; DEGRANULATION; DRUG EFFECT; FEMALE; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; INTRAPERITONEAL DRUG ADMINISTRATION; LOEFFLER PNEUMONIA; LUNG MYCOSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL TIME;

EID: 0031799529     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/515314     Document Type: Article

References (14)

1. Currie BP, Casadevall A. Estimation of the prevalence of cryptococcal infection among patients infected with the human immunodeficiency virus in New York City. Clin Infect Dis 1994;19:1029-33.
2. Levitz SM. The ecology of Cryptococcus neoformans and the epidemiology of cryptococcosis. Rev Infect Dis 1991;13:1163-9.
3. Mitchell TG, Perfect JR. Cryptococcosis in the era of AIDS - 100 years after the discovery of Cryptococcus neoformans. Clin Microbiol Rev 1995;8:515-48.
4. Murphy JW. Cryptococcal immunity and immunostimulation. Adv Exp Med Biol 1992;319:225-30.
5. Graybill JR, Alford RH. Cell-mediated immunity in cryptococcosis. Cell Immunol 1974;14:12-21.
6. Zuger A, Louie E, Holzman RS, Simberkoff MS, Rahal JJ. Cryptococcal disease in patients with the acquired immunodeficiency syndrome. Ann Intern Med 1986;104:234-40.
7. Zebedee SL, Koduri RK, Mukherjee J, et al. Mouse-human immunoglobulin G1 chimeric antibodies with activities against Cryptococcus neoformans. Antimicrob Agents Chemother 1994;38:1507-14.
8. Devi SJN, Schneerson R, Egan W, et al. Cryptococcus neoformans serotype A glucuronoxylomannan-protein conjugate vaccines: synthesis, characterization, and immunogenicity. Infect Immun 1991;59:3700-7.
9. Mukherjee S, Lee S, Mukherjee J, Scharff MD, Casadevall A. Monoclonal antibodies to Cryptococcus neoformans capsular polysaccharide modify the course of intravenous infection in mice. Infect Immun 1994;62:1079-88.
10. Mukherjee J, Scharff MD, Casadevall A. Protective murine monoclonal antibodies to Cryptococcus neoformans. Infect Immun 1992;60:4534-41.
11. Dromer F, Charreire J, Contrepois A, Carbon C, Yeni P. Protection of mice against experimental cryptococcosis by anti-Cryptococcus neoformans monoclonal antibody. Infect Immun 1987;55:749-52.
12. Mukherjee J, Pirofski L, Scharff MD, Casadevall A. Antibody-mediated protection in mice with lethal intracerebral Cryptococcus neoformans infection. Proc Natl Acad Sci USA 1993;90:3636-40.
13. Feldmesser M, Casadevall A. Effect of serum IgG1 to Cryptococcus neoformans glucuronoxylomannan on murine pulmonary infection. J Immunol 1997;158:790-9.
14. Dromer F, Perronne C, Barge J, Vilde JL, Yeni P. Role of IgG and complement component C5 in the initial course of experimental cryptococcosis. Clin Exp Immunol 1989;78:412-7.